Abbott Laboratories Under DOJ Investigation Into 2022 Baby Formula Plant Shutdown: Report
The Justice Department's consumer-protection branch is conducting an investigation into infant formula maker Abbott Laboratories (NYSE: ABT).
Noting Strong Progress On Marinus Pharma’s Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
RBC Capital Markets initiated coverage on Marinus Pharmaceuticals Inc (NASDAQ:MRNS) with an Outperform rating, Speculative Risk, and a price target of…
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Zymeworks Inc (NASDAQ:ZYME) announced tolerability and efficacy results, including the first overall survival (OS) data, from…
Surmodics Stock Slides Following Regulatory Setback For Its SurVeil Drug-Coated Balloon
Surmodics Inc (NASDAQ:SRDX) has received a letter from the FDA related to its premarket approval (PMA) application for the SurVeil drug-coated…
Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder
Horizon Therapeutics plc’s (NASDAQ:HZNP) Phase 2 trial evaluating dazodalibep for Sjögren’s syndrome met its primary endpoint in the second patient…
Johnson & Johnson’s HIV Vaccine Regimen Does Not Prevent Infection, Phase 3 Study Shows
The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced the results of an independent, scheduled data review of the Phase 3 Mosaico study of the investigational HIV vaccine regimen.
Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
Capricor Therapeutics (NASDAQ:CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor’s proprietary StealthX exosome platform’s therapeutic potential, generating…
Macro Factors Take a Toll on Cutera Earnings, Analyst Slashes Price Target by 61%
Earlier this week, Cutera Inc (NASDAQ:CUTR) reported interim FY22 sales of $252 million to $253 million for full-year 2022, growing 15% to…
BioMarin’s Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
Wedbush has increased the price target on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) from $74 to $84 while reiterating the Neutral rating. BioMarin reported three-year…